About Us
STI Pharma, LLC was founded by a team of industry veterans who together assembled a talented management team. Our strategy is to acquire specialized, niche-marketed products that have potential for growth and development through brand recognition, product life-cycle management, alternative indications and new dosage formulations.
Key Personnel
| Anup Dam, M.S. - Chairman and Manager | |
 |
As founder of STI Pharma, LLC, Mr. Dam utilized his more than 20 years of biomedical and related industry experience to develop and grow the company. His research and development experience began in 1986 with G.D. Searle (Pharmacia) and subsequently with Abbott Laboratories and Carter-Wallace Laboratories. He was Lead Analyst in the successful approval of such products as Ambien®, Astelin®, and Felbatol®. Mr. Dam founded STI Pharma, LLC in 2008 with the goal of building a risk-gated specialty pharmaceutical company with the acquisition , LCM development and marketing of pharmaceutical products in the Pain Management, Anti-infective and Respiratory markets. To date, STI Pharma has acquired products that include Myambutol®, Triacin-C®, Dexamethasone Elixir®, and Betamethasone® topical lotion. Mr. Dam received an M.S. in Statistics from the University of Illinois and also from Dhaka University in Bangladesh. |
| Bruce Simpson, M.B.A. - President and CEO | |
 |
As Chief Executive Officer of STI Pharma, LLC Mr. Simpson has over 35 years of experience in research and development, marketing, and business development. He has held senior level positions at leading companies such as Fisons Corportation and Medeva Pharmaceuticals and Adams Laboratories, where he was responsible for revenues in excess of $500 million. He has developed, acquired or managed leading products, including Tussionex®, Zaroxolyn®, and Methylphenidate. Mr. Simpson received his M.B.A. in Marketing from the University of Hartford and received his Post Graduate Certificate in Health Care Marketing from UCLA. |
| David F. Counts, Ph.D. - Director, Business Development | |
 |
Dr. Counts has over 20 years experience in the Pharma/Biotech Industry. His experience includes business development, acquisition of companies while at Marion Labs (American Biomaterials, now Integra Life Sciences), as well as negotiation of co-development agreements with both biotech companies and universities. Dr. Counts was Associate Vice President for technology evaluation and licensing at BTG in the US with a focus on the areas of inflammation and infectious diseases. As such, he acquired and licensed technologies from companies (DuPont, Merck and Biogen) and universities. Dr. Counts has helped start two biotech companies and one cosmetic company. |